Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
The GBG Annual Meeting will be held february 24th to 26th 2021 as a virtual conference.
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
The 17th St.Gallen International Breast Cancer Conference is going fully virtual!
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
First patient included.
NSABP and GBG are pleased to announce the 1000th patient has been randomized for the GeparDouze trial.
Analysis of breast cancer patients with asymptomatic brain metastases from BMBC registry has been published in Cancers (Basel).
A translational research project evaluating the MGMT promoter methylation status in TNBC from GeparSixto has been published in PLoSOne
The collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.
A research project investigating tumor mutational burden and immune gene expression profile for response to neoadjuvant treatment in early TNBC has been published in Annals of Oncology
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.